Aktis Oncology

Aktis Oncology is a biotechnology company pioneering the discovery and development of a new class of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. Founded and incubated by MPM Capital, the company has developed proprietary platforms to generate tumor-targeting agents with ideal properties for alpha radiotherapy. Designed for high tumor penetration and long residence time, Aktis Oncology's molecules will quickly clear other areas of the body, thereby maximizing tumor elimination while minimizing the side effects of treatment. This approach would also enable clinicians to visualize and verify target engagement prior to exposure to therapeutic radioisotopes.

Aktis Oncology headquartered in United States, North America, operates in the Biotechnology, Life Science, Health Care, Oncology sector. The company focuses on Biotechnology and has secured $7.5B in funding across 48 round(s). With a team of 11-50 employees, Aktis Oncology is actively contributing to advancements in Biotechnology. Their latest funding round, Corporate Round - Aktis Oncology, raised $Unknown amount. Discover more about their projects, partnerships, and impact on our platform.